Report Scope:
The current report will provide an in-depth look at the insulin drug and delivery technologies market. This report analyzes the market trends of insulin drug and delivery technologies with data from 2021, estimates from 2022, projections of compound annual growth rates through 2027 (forecast period 2022-2027), and regional markets of the insulin drug and delivery technologies. This report will highlight the current and future market potential of insulin drug and delivery technologies along with a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints and opportunities will be covered in the current report. The report also covers market projections for 2026 and market share for key market players.

In this report, the market has been segmented based on device type, insulin type and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens and others. Insulin types include long-acting, rapid-acting, premixed insulins, intermediate-acting and short-acting.

Geographic regions covered include North America, Europe, Asia-Pacific and the rest of the world (RoW). Individual countries covered include the U.S., Germany, the U.K., Italy, France, Japan, China and India.

Report Includes:

  • 24 data tables and 31 additional tables
  • An up-to-date review of the global markets for insulin drug and delivery technologies
  • Analyses of the global market trends, with historic market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the current state of the insulin drug and delivery industry structure, novel technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
  • Estimation of the actual market size and market forecast for insulin drug and delivery technologies, and corresponding market share analysis by device type, insulin type, and geographic region
  • Updated information on the key merger and acquisition deals, partnerships, collaborations and other strategic alliances within the insulin drug and delivery technologies industry
  • Analysis of market opportunities with a holistic review of the Porter’s Five Forces analysis model considering both the micro and macro environmental factors prevailing in the market
  • Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
  • Descriptive company profiles of key manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG